SUPPLEMENTARY TABLES

Supplementary Table 1. Multiple Cox proportional hazards regression for the estimation of adjusted hazard ratios for hemodialysis or peritoneal dialysis.

Variable	aHR[a] (95% C.I.)	
	Age-and sex-matched	PSM[b]
Anti-VEGF injection (ref: Control)	1.680 (1.358–2.078)	1.849 (1.378–2.482)
Sex		
Male	1.396 (1.111–1.753)	1.326 (0.951–1.849)
Female	Reference	Reference
Age at index		
20–40	1.312 (0.581–2.959)	1.297 (0.484–3.477)
40–60	Reference	Reference
60–80	0.629 (0.483–0.820)	0.707 (0.494–1.012)
80–100	0.597 (0.407–0.877)	0.670 (0.361–1.242)
Co-morbidities[c]		
Hypertension	1.832 (1.433–2.342)	1.791 (1.268–2.531)
Diabetes mellitus	2.696 (1.802–4.033)	4.062 (1.971–8.373)
Ischemic heart diseases	0.829 (0.587–1.172)	0.551 (0.304–1.001)
Hyperlipidemia	1.012 (0.831–1.232)	1.234 (0.930–1.638)
Congestive heart failure	2.238 (1.683–2.977)	1.651 (1.059–2.575)
Rheumatic disease	1.713 (0.705–4.163)	0.546 (0.075–3.983)
Kidney disease	3.156 (2.322–4.289)	3.420 (2.222–5.263)
CKD	2.284 (1.663–3.137)	1.844 (1.177–2.888)

Abbreviations: C.I.: confidence interval; CKD: chronic kidney disease; VEGF: vascular endothelial growth factor. [a]Adjusted hazard ratio (aHR): The covariates including year of index, sex, age, indication, urbanization, insured type, marital status, education level, co-morbidities at baseline. [b]Propensity score matching was done by matching: Year of index, Sex, Age at index, Indication, Urbanization, Insured unit type, Marital status, Education level, Co-morbidities (including Hypertension, Diabetes mellitus, Ischemic heart diseases, Hyperlipidemia, Congestive heart failure, and Rheumatic disease). [c]Co-morbidity were identified within 1 year before index date.

Supplementary Table 2. Multiple Cox proportional hazards regression for the estimation of adjusted hazard ratios for hemodialysis or peritoneal dialysis stratifying by different types of the anti-VEGF agents.

Variable	aHR[a] (95% C.I.)	
	Age-and sex-matched	PSM[b]
Model: type of Anti-VEGF		
No anti-VEGF	Reference	Reference
Ranibizumab	1.722 (1.388–2.136)	1.896 (1.409–2.551)
Aflibercept	1.031 (0.418–2.546)	1.166 (0.454–2.996)
Model: times of ranibizumab		
0	Reference	Reference
1	1.212 (0.497–2.952)	1.276 (0.511–3.185)
2	2.519 (1.456–4.357)	2.809 (1.566–5.036)
3	1.746 (1.253–2.433)	1.834 (1.236–2.722)
≥4	1.655 (1.266–2.164)	1.846 (1.321–2.578)

Model: times of aflibercept		
0	Reference	Reference
1	–	–
2	1.324 (0.184–9.537)	1.185 (0.161–8.704)
3	1.554 (0.381–6.335)	1.506 (0.361–6.278)
≥4	0.599 (0.147–2.431)	0.569 (0.138–2.351)

Abbreviations: C.I.: confidence interval; VEGF: vascular endothelial growth factor. [a]Adjusted hazard ratio: The covariates including year of index, sex, age, indication, urbanization, insured type, marital status, education level, co-morbidities at baseline. [b]Propensity score matching was done by matching: Year of index, Sex, Age at index, Indication, Urbanization, Insured unit type, Marital status, Education level, Co-morbidities (including Hypertension, Diabetes mellitus, Ischemic heart diseases, Hyperlipidemia, Congestive heart failure, and Rheumatic disease).

Supplementary Table 3. Diagnosis codes for study comorbidities.

Diseases	ICD-9-CM codes	ICD-10-CM codes
Chronic kidney disease	585	N18.4, N18.5, N18.6, N18.9
Congestive heart failure	398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 425.4–425.9, 428.x	I50.2x, I50.3x, I50.4x, I50.84, I50.89, I50.9
Diabetes mellitus	250.x, 277.7	O24.4, E11.x, E13.x, E88.81
Hyperlipidemia	272.0, 272.1, 272.2, 272.4, 272.9	E78.0x, E78.1, E78.2, E78.3, E78.4x, E78.5, E78.70, E78.79, E78.89, E78.9
Hypertension	401.x-405.x	I10, I11.x, I13.x, I15.x, I16.x, I87.3x, I97.3x, O10.x, O11.x, O13.x, O16.x
Ischemic heart disease	410-414	I20–I25
Kidney disease	403.x, 404.x, 582.x, 583.0–583.7, 585.x, 586.x, 588.x, V42.0, V45.1, V56.x	E08.2x, E09.2x, E11.2x, E13.2x, I12.x, I13.1, N03.x, N04.x, N11.x, N18.x, O10.2x, O10.3x, Z49.31, I95.3, T82.43XA, E85.3, R88.0, T82.4x
Rheumatic disease	446.5, 710.0, 710.1, 710.3, 710.4, 714.0–714.2, 714.8, 725.x	M05.1x, M05.2x-M05.9, M31.6, M32.1x, M32.8, M32.9, M33.03, M33.13, M33.2x, M33.90, M33.93, M34.0x, M34.1x, M34.9, M35.3